About US
Contact us
-
Bayer's now-approved Adempas girds for market-share battle in PAHBayerscored another R&D success with the FDA approval of Adempas (riociguat) for two rare pulmonary disorders. It's the first of a new generation of drugs for pulmonary arterial hypertension, and2013/10/10
-
Former Lilly scientists indicted for passing R&D secrets to Chinese drugmakerTwo former Eli Lilly ($LLY) scientists stand accused of passing laboratory trade secrets to a Chinese drugmaker. Guoqing Cao and Shuyu "Dan" Li are held without bail in Indiana, where they were indict2013/10/9
-
GlaxoSmithKline to seek EMA approval for 2015 malaria vaccine launchGlaxoSmithKline's ($GSK) experimentalmalariavaccine may not have delivered results as strong as the company hoped. But it does offer enough protection to slash the number of cases in infants for a tim2013/10/9
-
Merck puts Whitehouse Station HQ on the blockMerck's global headquarters is wearing a "For Sale" sign. The company said last year that it would pack up and leave Whitehouse Station, NJ, in a money-saving move. But now, the million-square-foot ca2013/10/8
-
Forget a Roche merger; Novartis sell-offs could be imminent, analyst saysConsumer health, animal health, vaccines and diagnostics all on the table, with decision expected soon News flash from Basel: Yes, Novartis really is considering selling off a few of its units, in de2013/10/8
-
U.K.'s nod to J&J's Caelyx comes even as shortages expectedJanssen has warned docs to expect shortages starting next month The U.K. drug price watchdog today gave Johnson & Johnson's ($JNJ) Caelyx the distinction of being one of only two drugs it believe2013/9/30
-
FTC tells Mylan to sell 11 drugs to complete $1.6B Agila dealTheU.S. Federal Trade Commissionfavors Mylan's ($MYL) $1.6 billion buyout ofAgila Specialties, but is insisting the companies sell off 11 injectable drugs in markets where it believes the deal would h2013/9/30
-
Japan authorities digging deeper into Novartis' use of flawed Diovan studySometimes saying you're sorry just isn't enough. Swiss drugmaker Novartis ($NVS)has repeatedly apologized after learning that a company employee was affiliated with a study in Japan of blockbusterDiov2013/9/29
-
Boehringer's China expansion hits as probes leave market in turmoilGermany'sBoehringer Ingelheimtwo years ago started on a major addition to its operations inChinaas that rapidly expanding market looked like the promised land to many drugmakers. But the new facilitie2013/9/29
-
Merck gives up on unsuccessful Januvia combo drug JuvisyncMerck ($MRK) may have some dark clouds hanging overhead, but its multibillion-dollar diabetes franchise can usually be counted on for a bit of shine. As it announced cuts to its full-year sales foreca2013/9/27